Theratechnologies (THTX) announced that a shortage of Egrifta SV will occur at the patient level in mid-January, following a voluntary shutdown of the contract manufacturing facility in 2024. While the Company is aware of remaining inventory of Egrifta SV in certain pharmacies throughout the United States, several pharmacies have reported stockouts. Theratechnologies filed a required prior approval supplement to the FDA on December 18, 2024. The company subsequently submitted questions as part of a Type D meeting request concerning the status of two recently manufactured batches of Egrifta SV(R), which are waiting to be released to pharmacies. The FDA confirmed that it would respond to the company’s questions in writing no later than February 8.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THTX:
- Impending Shortage of Theratechnologies’ EGRIFTA SV® Amid Manufacturing Shutdown
- Theratechnologies Seeks FDA Approval for Manufacturing Changes to EGRIFTA SV®
- Theratechnologies Seeks FDA Approval for EGRIFTA SV® Changes
- Theratechnologies announces filing of PAS with FDA for manufacturing environment
- Theratechnologies Secures Canadian Rights for Ionis RNA Medicines